Cargando…

Immune checkpoint inhibitor induced neurocognitive deficits in patients

This scientific commentary refers to ‘Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity’, by Farina et al. (https://doi.org/10.1093/braincomms/fcad169)

Detalles Bibliográficos
Autores principales:	Zeiser, Robert, Prinz, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Scientific Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10306159/ https://www.ncbi.nlm.nih.gov/pubmed/37389305 http://dx.doi.org/10.1093/braincomms/fcad186

Ejemplares similares

The gut microbiota and immune checkpoint inhibitors
por: Humphries, Audrey, et al.
Publicado: (2018)

Immune checkpoint inhibitor-related acral vasculitis
por: Comont, Thibault, et al.
Publicado: (2018)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis
por: Hottinger, Andreas F., et al.
Publicado: (2018)

Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
por: Belluomini, Lorenzo, et al.
Publicado: (2019)

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology
por: Jardim, Denis L., et al.
Publicado: (2018)

Antibiotic therapy and outcome from immune-checkpoint inhibitors
por: Pinato, David J., et al.
Publicado: (2019)

COVID-19 and immune checkpoint inhibitors: initial considerations
por: Sullivan, Ryan J, et al.
Publicado: (2020)

Immune checkpoint inhibitors: here to stay
por: Carvalho, Filomena Marino, et al.
Publicado: (2023)

Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors
por: Mundra, Vatsala, et al.
Publicado: (2023)

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
por: Akhuba, Liia, et al.
Publicado: (2023)

Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity
por: Lee, Karla A, et al.
Publicado: (2020)

Taking the bull by the horn: the frontline use of infliximab for the treatment of immune checkpoint inhibitor-induced enterocolitis
por: Esfahani, Khashayar
Publicado: (2018)

A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
por: Haratani, Koji, et al.
Publicado: (2020)

Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC
por: Papavassiliou, Kostas A., et al.
Publicado: (2023)

Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors
por: Bersanelli, Melissa
Publicado: (2020)

How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases?
por: Minami, Yasunori, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Mismatch Repair Proficient/Microsatellite Stable Metastatic Colorectal Cancer Patients: Insights from the AtezoTRIBE and MAYA Trials
por: Germani, Marco Maria, et al.
Publicado: (2021)

Considerations for Use of Immune Checkpoint Inhibitors in Cancer Therapy for Patients with Co-Existing Thyroid Eye Disease
por: Chau, Charlene Y. C., et al.
Publicado: (2020)

Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
por: Haanen, John, et al.
Publicado: (2020)

A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer
por: Antonarakis, Emmanuel S.
Publicado: (2019)

Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer
por: Yu, Peter Paul, et al.
Publicado: (2019)

Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment
por: Rossi, Ernesto, et al.
Publicado: (2020)

Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology
por: Özdemir, Berna C
Publicado: (2021)

Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis
por: Xavier, Camila Bragança, et al.
Publicado: (2022)

Immune checkpoint inhibitor in liver cancer—unique regional differences
por: Obi, Shuntaro, et al.
Publicado: (2020)

Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?
por: Dillman, Robert O.
Publicado: (2016)

Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action
por: Neilan, Tomas G., et al.
Publicado: (2018)

Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19
por: Gatto, Lidia, et al.
Publicado: (2020)

Consideration of Severe Coronavirus Disease 2019 As Viral Sepsis and Potential Use of Immune Checkpoint Inhibitors
por: Odabasi, Zekaver, et al.
Publicado: (2020)

Immune checkpoint inhibitors and the shared epitope theory: from hypothesis to practice
por: Lerrer, Shalom, et al.
Publicado: (2019)

Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions?
por: Metro, Giulio, et al.
Publicado: (2020)

Neurocognitive dysfunction in mood disorders
por: Moore, Brian P., et al.
Publicado: (2003)

Increased abscopal responses after radiation therapy for oligoprogressive patients receiving immune checkpoint inhibitors?
por: Doyen, Jérôme, et al.
Publicado: (2023)

Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a “common language” for the new arena of cancer treatment
por: Nishino, Mizuki
Publicado: (2016)

Inhibiting an inhibitor: a decoy to recover dexterity after spinal cord injury
por: Bradbury, Elizabeth J, et al.
Publicado: (2020)

Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer’s disease and related dementias?
por: Newby, Danielle
Publicado: (2022)

High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
por: Maleki Vareki, Saman
Publicado: (2018)

Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
por: Miura, Yosuke, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7kd1q8s2u6aeos6oo5l9ed6drt